Literature DB >> 22727967

Increasing CHADS₂ scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding.

Davide Capodanno, Piera Capranzano, Giuseppe Giacchi, Valeria Calvi, Corrado Tamburino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22727967     DOI： 10.1016/j.ijcard.2012.06.029

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  2 in total

Review 1.  Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

Authors:  Louise Justesen Hesselbjerg; Heidi Sjoelund Pedersen; Mikael Bergholdt Asmussen; Karin Dam Petersen
Journal:  J Med Econ       Date:  2013-05-15       Impact factor: 2.448

2.  Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation.

Authors:  Brian M Salata; David W Hutton; Deborah A Levine; James B Froehlich; Geoffrey D Barnes
Journal:  Am J Cardiol       Date:  2015-10-19       Impact factor: 2.778
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.